The US Food and Drug Administration recently approved Aduhelm, a monoclonal antibody that targets amyloid beta (A), as the first Alzheimer disease treatment (
The US Food and Drug Administration recently approved Aduhelm, a monoclonal antibody that targets amyloid beta (A), as the first Alzheimer s disease treatment (AD)
Although Aduhelm, a monoclonal antibody targeting amyloid beta (Aβ), recently became the first US FDA approved drug for Alzheimer's disease (AD) based on its ability to decrease Aβ plaque burden in AD patients, its effect on cognitive improvement is still controversial.
Aduhelm, a monoclonal antibody that targets amyloid beta (A), was recently found by the US Food and Drug Administration as the first treatment for Alzheimer s disease (AD)